All lobbying filings

Forbes-Tate

Forbes-Tate filed a Q3 report for Halozyme Therapeutics, Inc. on October 18, 2025, reporting $60,000 in lobbying income.

Lobbying for Halozyme Therapeutics, Inc. · U.S. Biotechnology Company

As filed: FORBES-TATE for HALOZYME THERAPEUTICS, INC.

All filings by Forbes-Tate · Everything Halozyme Therapeutics, Inc. has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2025

July 1 - Sep 30 · Posted Oct 18, 2025

Income

$60,000

What the client paid this registrant for the period.

Client based in

California

Official filing document

Government bodies contacted 4

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Health Issues

Issues related to biopharmaceutical research, development, and manufacturing.

Medicare/Medicaid

Issues related to coverage and reimbursement.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.